Skip to main content

Table 1 Patient characteristics

From: The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010

n 2,863
Age, mean ± SD 66.71 ± 9.149
Sex (male), n (%) 1,478 (51.6%)
Smoking history, n (%) 1,471 / 2,779 (52.9%)
Procedure, n (%)
 Lobectomy 2,863 (100%)
 Operation time (min.), mean ± SD 205.3 ± 66.89
Histological subtype, n (%)
 AIS 135 (4.7%)
 MIA 175 (6.1%)
 Invasive adenocarcinoma 2,506 (87.5%)
 Lepidic 521 (18.2%)
 Acinar 537 (18.8%)
 Papillary 1,161 (40.6%)
 Micropapillary 63 (2.2%)
  Solid 224 (7.8%)
  Variants 47 (1.6%)
Invasion
 Lymph vessel invasion ( ±), n (%) 777 / 1,785 (30.3%)
 Vascular invasion ( ±), n (%) 695 / 1,875 (27.0%)
 Pleural invasion ( ±), n (%) 691 / 2,156 (24.3%)
 EGFR status ( ±), n (%) 641 / 783 (45.0%)
 Adjuvant chemotherapy ( ±), n (%) 1,017 / 1,820 (35.8%)
Clinical stage, n (%)
 Stage IA 1732 (60.5%)
 Stage IB 749 (26.2%)
 Stage IIA 190 (6.6%)
 Stage IIB 83 (2.9%)
 Stage IIIA 98 (3.4%)
Pathological stage, n (%)
 Stage IA 1,426 (49.8%)
 Stage IB 732 (25.6%)
 Stage IIA 260 (9.1%)
 Stage IIB 110 (3.8%)
 Stage IIIA 314 (11.0%)
  1. AIS Adenocarcinoma in situ, MIA Minimally invasive adenocarcinoma, SD standard deviation, Min Minutes